



Cite this: *Integr. Biol.*, 2016, 8, 761

Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia†

Jennifer L. Wilson,^a Simona Dalin,^b Sara Gosline,^a Michael Hemann,^b Ernest Fraenkel^{*ab} and Douglas A. Lauffenburger^{*a}

Data integration stands to improve interpretation of RNAi screens which, as a result of off-target effects, typically yield numerous gene hits of which only a few validate. These off-target effects can result from seed matches to unintended gene targets (reagent-based) or cellular pathways, which can compensate for gene perturbations (biology-based). We focus on the biology-based effects and use network modeling tools to discover pathways *de novo* around RNAi hits. By looking at hits in a functional context, we can uncover novel biology not identified from any individual 'omic measurement. We leverage multiple 'omic measurements using the Simultaneous Analysis of Multiple Networks (SAMNet) computational framework to model a genome scale shRNA screen investigating Acute Lymphoblastic Leukemia (ALL) progression *in vivo*. Our network model is enriched for cellular processes associated with hematopoietic differentiation and homeostasis even though none of the individual 'omic sets showed this enrichment. The model identifies genes associated with the TGF-beta pathway and predicts a role in ALL progression for many genes without this functional annotation. We further experimentally validate the hidden genes – Wwp1, a ubiquitin ligase, and Hgs, a multi-vesicular body associated protein – for their role in ALL progression. Our ALL pathway model includes genes with roles in multiple types of leukemia and roles in hematological development. We identify a tumor suppressor role for Wwp1 in ALL progression. This work demonstrates that network integration approaches can compensate for off-target effects, and that these methods can uncover novel biology retroactively on existing screening data. We anticipate that this framework will be valuable to multiple functional genomic technologies – siRNA, shRNA, and CRISPR – generally, and will improve the utility of functional genomic studies.

Received 18th March 2016,
Accepted 31st May 2016

DOI: 10.1039/c6ib00040a

www.rsc.org/ibiology

Insight, innovation, integration

This work integrates multiple 'omic data sets to better understand leukemia pathology. The most striking finding in this work is that we can identify biological annotations from these data when these datasets are integrated in a network model even though these annotations were not present in any individual input dataset. Further, we use RNAi screening data as the model's foundation; this screening technology is a popular tool for probing gene function that is criticized for noise and off-target effects. With integration, we derive novel insights in spite of this noise and are able to test our theoretical findings through dedicated validation.

Introduction

Functional genomic screens are a powerful tool for systematically probing gene function in the context of many biological systems.^{1–6}

Shortly after its adaptation to experimental work, RNAi gained popularity as the technology is relatively easily and quickly adaptable to multiple biological systems.^{3,5,6} However, off-target effects (OTEs) which can result from seed matches between the individual RNAi and unintended genes⁷ are a widely criticized limitation of this technology. These effects complicate validation and pursuit of further hypotheses^{6,8,9} and thus, RNAi screens require analysis methods that can more efficiently identify true targets for validation.^{6,7} Many studies have focused on improving the stability and specificity of the RNAi reagents themselves,¹⁰ or have developed algorithms for predicting real effects by

^a Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 16-343, Cambridge MA 02139, USA.

E-mail: fraenkel@mit.edu, lauffen@mit.edu; Tel: +1-617-252-1629

^b Department of Biology, Massachusetts Institute of Technology, Cambridge MA 02139, USA

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ib00040a



considering unintended seed matches.^{8,11,12} Other studies have considered alternative platforms, such as TALENS or CRISPR, for probing gene function.⁵ CRISPR systems can exhibit stronger loss of function phenotypes than RNAi and seem a promising alternative.¹³ These systems enable precision genome engineering by more efficiently blocking gene function, and have the added capacity of being able to activate and inactivate genes.¹³ CRISPR systems still suffer from OTEs and are sensitive to mismatches in the 12 bases proximal to the guide strand.¹⁴ Overall, these approaches only address the technical challenges of gene interference and do not consider the biological consequences.

Few investigations have considered how a cell may compensate for a gene perturbation. An RNAi reagent may perfectly block an mRNA transcript, but a redundant protein may compensate for the loss of a particular gene or the targeted protein may be stable beyond the duration of knockdown, leading to false negatives. Further reasons for false negatives include the inability for RNAi to sufficiently diminish expression of highly stable proteins (*e.g.* enzymes which may retain function after knockdown) or the use of small, targeted libraries. To compensate for the possibility of false positives and false negatives, one group used GO analysis to find consensus among three different siRNA screens for HIV replication factors. The group saw little overlap between the specific hits from each screen, but saw that all three screens had top hits enriched for the same GO functions.¹⁵ Given the propensity for OTEs, it is not surprising that three independent screens identified different candidate hits, but it is striking that the individual hits fall in similar pathways.¹⁵ This work foreshadows the value of using pathways to provide context around any individual hit. However, our current definitions of cellular pathways are incomplete and there is a real need for discovering pathways and attributing new genes to existing pathways.

Here we pursued an integrated, pathway-based approach to identify *in vivo* specific regulators of acute lymphoblastic leukemia (ALL) progression. Development of treatments for acute lymphoblastic leukemia (ALL) has had mixed success and improvements in patient overall survival is still unchanging.¹⁶ For childhood ALL patients, 10% suffer remissions and these treatments have high toxicity.¹⁷ We already know that the tumor microenvironment affects how cancers progress and respond to therapies in a complex manner. Paracrine signaling in the bone-marrow microenvironment can confer resistance to therapy in myeloma¹⁸ and local cytokines can promote cancer development in the context of specific genetic lesions.¹⁹ More thorough disease characterization in the native microenvironment would facilitate development of new treatment strategies. Further, ALL is just one of many types of cancers which arises from incomplete hematopoietic differentiation. Given the similar origin of these diseases, it is possible that we can learn and repurpose molecular studies from other hematopoietic cancers to accelerate development for ALL. Already, we have used a genome-wide shRNA screen to discover genetic mediators of pre-B-cell ALL progression *in vivo*, and demonstrated the ability to identify micro-environment-specific genes affecting improper B-cell development.²⁰

Recognizing the likelihood of significant OTEs and acknowledging the significant merits of pathways analysis methods, we developed a network model to discover missed targets, or predicted genes, from the initial shRNA screen. This network model builds on the pathway-based approach described earlier by incorporating diverse experimental datasets to better model the genes contributing to ALL progression. We assume that many pathway annotations are incomplete, and that modeling multiple experimental datasets will uncover novel pathways. We construct our network model using shRNA, ChIPseq, and mRNA expression data and use this model to understand and validate features of the *in vivo* system. We experimentally validate novel roles for Hgs and Wwp1: Hgs is a gene that is generally deleterious to B-cell ALL viability, and Wwp1 is an *in vivo* specific regulator of disease progression. We perform this analysis using screening data that was not designed for further computational modeling in mind – the screen did not contain redundant shRNAs or non-targeting controls. Taken together these results demonstrate the ability of network models to select candidate targets from an shRNA screen and discover novel pathways from disparate datasets. Biologically, the model makes specific predictions about gene targets that affect ALL progression by affecting the tumor microenvironment, illuminating multiple pathways that are relevant for therapeutic development in ALL.

Results

A network-based data integration scheme

To identify pathways that mediate ALL progression, using multiple experimental data – we introduce a network-based approach, described in Fig. 1. Conceptually, this approach uses published protein–protein interaction data (Fig. 1A) alongside computational derived protein–DNA interactions to construct a set of all possible interactions that can relate experimental measurements from shRNA screening and mRNA expression. This larger network will then be reduced (Fig. 1B and C) to identify biological pathways, either known or unknown, that are implicated by the experimental data, described below.

shRNA screen and mRNA expression data identify distinct and incomplete gene sets

We collected previously-published shRNA screens and mRNA expression data from a mouse model of ALL, one *in vitro* and the other *in vivo*²⁰ (Fig. 1D). Together this data represents the direct and indirect effects of RNA knockdown in both environments.

To identify the direct effects of shRNA screens, we calculated a fold-change in shRNA representation, comparing sequencing reads for each shRNA at input (time of transplant) and post disease burden (at morbidity). We ranked genes based on the greatest depletion from input to post disease burden and considered the top 1% (84/87 genes for the *in vivo/in vitro* screens) for further investigation (Table 1). GO enrichment of the ranked list, using GOrilla^{21,22} of targets from the *in vivo* dataset did not identify any enrichment of GO terms. GO enrichment of






Fig. 1 Constructing a network model from multiple 'omic measurements. (A) We start with a probabilistic interactome that includes protein–protein interactions scored by the confidence of their interaction. This confidence score reflects the strength of evidence across multiple interaction databases and this score constrains the edge's capacity within our flow-based model. Higher confidence leads to higher capacity. Some of these proteins are transcription factors (triangles). We complement these edges with transcription-factor (triangles) to DNA (octagons) binding interactions. We predict these interactions and their edge probabilities by measuring active and open chromatin via ChIP-seq and looking for enrichment of transcription factor binding motifs. Conceptually, this is our available road map for creating pathways where the capacities are akin to speed limits. (B) We connect an artificial source node to all proteins that have corresponding shRNAs that were considered hits in the screen. These edge capacities reflect the strength of the shRNA effect. In our model, these edges reflect how strongly an shRNA depletes from input to morbidity. We connect an artificial sink node to differentially expressed mRNAs. These edges reflect the fold-change in expression. The algorithm introduces flow into the network and looks for an optimal route from the source to the sink, selecting edges based on available capacity. (C) The final path through the interactome becomes the *de novo* pathway. This pathway may or may not include all of the original inputs (e.g. differentially expressed mRNA or depleted shRNAs). Further, SAMNet allows the simultaneous construction of pathways for multiple conditions. In our investigation we treated the parallel *in vitro* and *in vivo* screens as separate conditions. (D) Screening design interrogates *in vivo* specific regulators of ALL progression. A genome-scale library was introduced to ALL cells *in vitro*. Representative samples were either maintained in culture or transplanted into mouse models. At time of morbidity, blood and culture samples were re-sequenced to measure shRNA representation.

the ranked *in vitro* targets found enrichment of cellular homeostasis, and cation regulation; however, these terms were enriched merely based on the presence of TMEM165, KCNA5, and CEBPA, without contribution from any other targets in the ranking (Table 2). Overall, we found little functional enrichment or information from shRNA data alone, suggesting that we had an incomplete picture of genes regulating ALL progression.

Using microarrays, we also collected differential mRNA expression data to compare between cellular contexts at morbidity. Genes were considered based on their fold-change relative to the *in vivo* context, and ranked based on fold-change. Again, we investigated the top 1% of genes up-regulated *in vivo* (77 genes) and up-regulated *in vitro* (66 genes) (Table 3). Using GOrilla, we found few enriched GO terms in the *in vivo* data genes as compared to the whole genome; these terms included regulation of transport, and actin cytoskeleton organization (Table 4). There were no enriched GO terms in the set of genes up-regulated in the *in vitro* context. We would expect that for any biological process, not all relevant genes will be differentially expressed or be sensitive to shRNA perturbation. Given these circumstances, we would not expect differential expression analysis or shRNA screening to uncover all relevant genes or expect these measurements to identify the same genes. The fact that there was little functional enrichment in these

top candidates reaffirms the incomplete nature of individual high-throughput measurements,^{2,3} and suggests an integrated approach could find hidden information.

Measuring histone activation for model specificity

When designing this model, we wanted to find interaction sets that connected the genes identified from the shRNA screen and from differential expression analysis. This model required protein to DNA interactions in addition to the existing protein to protein interactions in our interactome (Fig. 1A). These interactions were not publically available so we used a combined computational and experimental approach. Specifically, we used measurements of open and active chromatin to identify regions of putative transcriptional activity and predicted transcription factor to DNA binding interactions using computational modeling techniques.

We collected ChIP-seq data for the activating histone markers H3K27Ac and H3K4me3 from our ALL model in culture. Compared to an IgG control, we identified 29 468 and 18 142 peaks in the H3K27Ac and H3K4me3 datasets respectively. To identify regions of possible transcription factor binding, we searched within these peak regions for local minima, or valleys, between histones; from this analysis we found 70 894 and 24 617 valley sequences in the H3K27Ac and H3K4me3 datasets.



Table 1 Top 1% of depleting shRNAs *in vitro* and *in vivo*. We calculated the absolute values of fold-changes for all genes that depleted from input to end point. We mapped all genes to their human homologues for use with SAMNet. Fold-changes were calculated using DESeq2

Gene	Abs (f.c.)
<i>In vivo</i>	
ASRGL1	10.818
FNDC5	10.233
MRPL37	9.670
ATP6V1C1	9.478
DHX37	9.244
NRG2	9.155
ATP10B	8.940
HOXD3	8.765
HDHD1	8.760
PCBP4	8.744
DHDDS	8.633
SERF1A	8.474
SLC29A2	8.390
STK32B	8.296
POLQ	8.241
GTF3C5	8.164
SPC24	8.140
IPO11	8.102
GMPS	8.102
UBE2H	8.073
ZNF416	8.025
CASP14	8.014
SCD	8.000
MAPRE3	7.898
PLEKHA5	7.879
SMARCD1	7.856
DENND1C	7.840
TMEM156	7.821
TMEM176A	7.800
LPPR5	7.751
SRP72	7.704
ATP6AP2	7.595
FOXO6	7.588
WISP3	7.564
LCE3C	7.562
ZBTB4	7.512
RCC1	7.512
FXYD6	7.512
UBE2L6	7.505
SNTB1	7.498
TIMD4	7.480
DVL1	7.452
COLEC12	7.440
DHRS7C	7.440
CTSC	7.435
CECR5	7.425
IQCH	7.425
MTRF1L	7.366
TGS1	7.337
TIGD5	7.327
SPATA13	7.306
CPSF6	7.296
NDUFS1	7.292
ARMCX6	7.281
OR13C4	7.275
BCMO1	7.270
SF3A1	7.268
DIAPH3	7.266
PGLYRP2	7.249
ABHD12B	7.242
DRD1	7.241
ODF2	7.238
POGZ	7.215
TDRD7	7.206
C9orf69	7.193
ALKBH2	7.143

Table 1 (continued)

Gene	Abs (f.c.)
GRHL3	7.119
C17orf97	7.111
SUZ12	7.111
TMEM79	7.106
LAG3	7.062
IDH3A	7.042
C4orf32	7.039
PNO1	7.018
FUT10	7.005
VCPIP1	6.990
TFDP1	6.974
RPL7	6.966
RNF11	6.956
SLC6A2	6.951
YEATS2	6.932
LAP3	6.928
ADAMTS18	6.927
TRIM33	6.916
<i>In vitro</i>	
C10orf71	10.038
KCNA5	9.965
TMEM165	9.751
C1orf85	9.671
KLF3	9.633
CEBPA	9.333
TPSG1	8.975
ZNF367	8.826
GTPBP10	8.774
MFSD3	8.754
GLB1L	8.558
DNMT	8.498
MYT1	8.285
ANKS6	8.262
KRT77	8.160
NRARP	8.103
PPP3CB	8.099
MAD2L1	8.055
CRNKL1	8.016
ACTC1	8.016
AHCYL1	8.016
FCRL3	7.996
SURF4	7.996
RCOR2	7.962
FCGR3A	7.955
ZNF616	7.913
BAG5	7.902
SASS6	7.803
SMYD5	7.760
TRIM59	7.745
ZNF347	7.723
NFAT5	7.721
MATR3	7.649
MED8	7.643
CCT2	7.550
RAB33A	7.545
MCPH1	7.440
KCTD1	7.407
POLR3GL	7.380
MPZL1	7.365
INTS1	7.341
DNMT3A	7.334
ARL9	7.304
DOK2	7.285
SYNJ2	7.285
MBTPS2	7.228
C4orf17	7.183
NHLRC1	7.107
ATXN3	7.090




Table 1 (continued)

Gene	Abs (f.c.)
MID2	7.090
CHM	7.022
MEIS1	6.997
ZNF583	6.922
LAT	6.909
ZNF217	6.908
TPRKB	6.893
POLR2B	6.881
SPIRE1	6.849
ENO3	6.826
ZKSCAN2	6.722
C1orf106	6.694
REG1A	6.675
ZBTB24	6.667
TTL9	6.663
ITGB1BP1	6.633
IL5RA	6.607
SNTB2	6.598
AKR1D1	6.560
ZFYVE26	6.554
MRPL13	6.484
TDGF1	6.457
LGALS7	6.428
GCH1	6.378
DSEL	6.301
EIF2S3	6.300
S100A4	6.299
MRO	6.279
HMG2A	6.157
RASL10A	6.154
GIT2	6.148
PPARG	6.131
SCLT1	6.104
ASXL2	6.091
TM7SF3	6.078
NOS3	6.044
BICD1	6.040
NR3C1	6.035

Table 2 GO enrichment of shRNA targets from the *in vitro* screen. Enrichment used a single ranked list against the whole genome *via* the GOrilla web tool. There were no enriched GO terms for the genes selected by the *in vivo* screen

Go process	FDR q -value
Cellular homeostasis	3.79×10^{-2}
Ion homeostasis	4.07×10^{-2}
Cellular divalent inorganic cation homeostasis	4.38×10^{-2}
Divalent inorganic cation homeostasis	4.74×10^{-2}
Cellular chemical homeostasis	5.17×10^{-2}
Cation homeostasis	5.69×10^{-2}
Calcium ion homeostasis	6.32×10^{-2}
Metal ion homeostasis	7.12×10^{-2}
Monovalent inorganic cation homeostasis	8.13×10^{-2}
Chemical homeostasis	9.32×10^{-2}
Inorganic ion homeostasis	9.49×10^{-2}
Metal ion transport	1.14×10^{-1}
Cellular cation homeostasis	1.42×10^{-1}
Cellular metal ion homeostasis	1.90×10^{-1}
Cellular ion homeostasis	2.85×10^{-1}
Cellular calcium ion homeostasis	5.69×10^{-1}

Of these valleys, 15 178 regions overlapped between the two datasets (21% of the H3K27Ac and 62% of the H3K4me3). Fig. 2 shows example ChIP-seq reads, MACS peaks, valley regions,

and IgG controls for 3 control genes: Trim27, E2f3, and Hist1h1b. We selected these example genes because they had relevant histone activation marks in mouse B-cell samples that were previously published in the UCSC Genome Browser. From existing data, we expected to measure activation, and used these results to benchmark the quality of our experimental data prior to computational analysis. For these genes, the H3K4me3 and H3K27Ac ChIP-seq and MACs peaks were well aligned, although the valleys varied slightly. In the case of Hist1h1b, the H3K27Ac data had a larger MACs peak and thus more valley regions. Given these trends, we used the union of all valley regions to identify possible regions of transcription factor binding.

From these active valley regions, we used our own software suite, Garnet, to identify transcription factor to DNA binding interactions. Garnet uses a weighted scoring approach to quantify the probability that a transcription factor occupies a region based on the strength of the transcription factor motif.^{24,25} The analysis created a list of 262 705 interactions with scores above 0.3. We select 0.3 as a lower-bound for selecting interactions to reduce computational time. The algorithm is incentivized to use higher quality (*i.e.* higher scored) interactions, and so eliminating the weakest interactions creates smaller data objects. The upper bound is 0.99 because Garnet creates a normalized score. We append these interactions to an existing protein–protein interaction network derived from iRefWeb (interactome described in methods).

SAMNet identifies a network of genes affecting ALL progression

As we already knew that shRNA and mRNA measurements capture distinct pathway components,²³ we pursued a data integration approach to predict new genes in the ALL progression pathway. We used the Simultaneous Analysis of Multiple Networks (SAMNet)²⁶ to construct such a pathway because this was the most powerful tool given the data we had collected. The algorithm integrates diverse perturbation and response datasets and maps them to a physical interaction network comprising all possible ways by which the perturbed species (*e.g.* shRNA hits) can give rise to the observed response (*e.g.* differentially expressed transcripts). SAMNet then applies a network flow-based paradigm to select a subset of interactions that relates the experimentally-perturbed genes from the shRNA screen to the differentially expressed mRNA through the specified interactome. We conceptually depict how SAMNet integrates shRNA and mRNA data with our interaction network, or interactome in Fig. 1. In the context of the resulting model, RNAi genes are connected upstream of transcription factors and differentially-expressed mRNAs; sometimes, RNAi genes represent transcription factors themselves and are directly connected to differential mRNAs. Mathematically, the algorithm selects an interaction sub-network by pushing flow through a probabilistically-weighted interactome (described in methods). Flow initiates at the RNAi hits and terminates on differentially expressed mRNAs. Fold-change values from RNAi and mRNA expression data constrain the amount of flow any experimental gene hit can capture in the network. Genes are able to capture flow from either commodity, and interactions can be shared between commodities if the algorithm identifies that these interactions can connect data from both experimental environments.



Table 3 Genes selected as top candidates from mRNA expression data. The table shows the top 1% of genes up-regulated *in vivo* (top) and *in vitro* (bottom)

<i>In vivo</i> , genes with fold-change values					
HBA-A1	12.10	LOC671894///LOC674	7.75	MYOM2	7.03
S100A9	11.93	RTP4	7.63	MX1	7.01
S100A8	10.92	MS4A1	7.61	TIAM1	7.00
IIGP1	9.91	4732416N19RIK	7.57	D430019H16RIK	6.97
RHOJ	9.80	2900041A09RIK	7.56	DOCK9///LOC670309	6.96
NKG7	9.76	CASP4	7.55	SPARC	6.96
AQP1	9.75	IFITM3	7.53	FPR-RS2	6.93
ANXA2	9.64	SLFN4	7.53	PLF///PLF2///MRP	6.91
CSF1R	8.94	5830431A10RIK	7.49	MYH6///LOC671894/	6.81
IL18	8.85	ZBP1	7.44	CCL3	6.75
NRP1	8.68	B230343A10RIK	7.41	S100A5	6.73
FOS	8.52	CCL5	7.37	TIMM8A2	6.72
SAA3P	8.47	4921525O09RIK	7.36	LGMIN	6.69
CHI3L3	8.45	C5AR1	7.33	DLGH3	6.65
TCRB-J///TCRB-V13	8.29	C1QB	7.30	ITGA5	6.65
LOC240327	8.27	HTRA3	7.28	KLK3	6.64
IGL-V1///2010309G2	8.26	LAMB2	7.26	LGALS3BP	6.64
ENPP3	8.24	PLXNB1	7.25	CD97	6.63
PGLYRP1	8.19	IL2RA	7.24	DIRAS2	6.60
SLC9A3R2	8.11	A330102K04RIK	7.19	KLF4	6.55
LCN2	8.00	GPRC5A	7.16	GZMA	6.52
BLR1	7.90	TCRB-V13///LOC6655	7.12	2010300C02RIK///LO	6.51
HYDIN	7.89	TYROBP	7.10	ADCY6	6.51
EPPK1	7.88	1100001G20RIK	7.05	A930013B10RIK	6.49
NGP	7.82	LMNA	7.04	TLR1	6.48
MPA2L///LOC626578	7.80	XDH	7.04		
<i>In vitro</i> , genes with fold-changes					
TGFB3	-9.74	IL21R	-4.82	5730442G03RIK	-3.78
HBB-BH1	-8.50	BEX6	-4.57	1700025G04RIK	-3.77
VLDLR	-7.05	1190002F15RIK	-4.39	B230107K20RIK	-3.77
HS3ST1	-6.99	FETUB	-4.34	JDP2	-3.77
PLA2G2F	-6.02	NUPR1	-4.33	NETO2	-3.76
1700097N02RIK	-5.97	REEP1	-4.29	PRG3	-3.69
NKX1-2	-5.77	GLRP1	-4.25	RTN4RL2	-3.57
ACTR3B	-5.69	SENP8	-4.17	SLC6A13	-3.57
PPP1R3B	-5.52	CCR2	-4.15	D19ERTD652E	-3.53
UBQLN2	-5.49	PAX7	-4.13	ORC1L	-3.51
ANKRD15	-5.42	POLH	-4.10	CD248	-3.51
SOX6	-5.38	2610019I03RIK	-4.05	DPM3	-3.48
CDH1	-5.37	FADS2	-4.03	GM129	-3.48
1810011H11RIK	-5.35	DKK3	-3.99	USP2	-3.48
CD28	-5.20	PKP2	-3.95	EVA1	-3.45
LOC433844	-5.13	AXIN2	-3.92	ABCG1	-3.44
A1427515	-5.09	KIF2C///LOC631653	-3.88	AMMECR1	-3.43
ART4	-5.01	NAP1L3	-3.84	CMAH	-3.42
PTGS1	-4.95	2610021K21RIK	-3.83	PLK1	-3.40
GFI1B	-4.95	BARD1	-3.83	ZDHHC2	-3.39
SELENBP1	-4.93	CHAC1	-3.80	GCM2	-3.39
CTH	-4.93	4731417B20RIK	-3.79	MAP6	-3.38

Table 4 GO enrichment for genes up-regulated *in vivo*. Enrichment used a single ranked list against the whole genome *via* the GOrilla web tool. There were no enriched GO terms for genes up-regulated *in vitro*

GO function	FDR <i>q</i> -value
Regulation of transport	1.24×10^{-1}
Response to transition metal nanoparticle	1.96×10^{-1}
Positive regulation of transport	2.15×10^{-1}
Actin filament-based process	2.46×10^{-1}
Actin cytoskeleton organization	3.27×10^{-1}

The foundational model consisted of 311 nodes and 480 edges (full network available at <http://fraenkel-nsf.csbi.mit.edu/psiquic/cytoscape.html>). We proceeded from this foundation by

removing the ‘source’ and ‘sink’ nodes which are topological formalities for creating the network model. This created an interaction network where upstream protein–protein interactions converge on transcription factor to DNA binding interactions. To first focus on a protein interaction sub-network, we omitted the 43 mRNA nodes and transcription factors that are not directly connected to the protein–protein interactome (see below). The resulting sub-network contains 258 nodes and 259 edges (Fig. 3). This network contained 91 targets from the RNAi inputs (*i.e.* experimental genes), and 167 predicted genes. Of the 167 predicted genes, 33 are transcription factors.

A predicted transcription factor to DNA binding sub-network contains 84 nodes with 79 edges (Fig. 4); 41 nodes are






Fig. 2 ChIP-seq with valley-finding identifies regions for transcription-factor binding. Genome viewer tracks for Trim27 (chr13:21,267,345–21,277,316), E2f3 (chr13:30,071,171–30,083,320), and Hist1h1b (chr13:21,868,763–21,874,488), showing ChIP-seq reads (top), MACs peaks (middle), valley regions (lower, orange), and IgG control (grey, lower) for H3K27Ac (top 4 rows) and H3K4me3 (bottom 4 rows). The valleys highlight regions where we searched for transcription factor binding motifs.




Fig. 3 SAMNet identifies integrated network for ALL progression. The purple/green edges represent interactions from the *in vivo/in vitro* screens. RNAi hits are represented by a shaded square; the shading refers to the extent of depletion in the original screen. A diamond is a transcription factor selected by SAMNet; those that are shaded are also hits from the shRNA screen. All white-face nodes are hidden targets selected by the algorithm. Node border color represents fractional representation in a family of 100 random networks. Those without pink/orange border coloring are non-specific. The thickness of the interaction line represents the amount of flow captured by that interaction; qualitatively this reflects an edge with higher interaction confidence in the underlying interactome. Downstream mRNA pictured in Fig. 4. Red arrows indicate where Wwp1, Hgs, Lmo2, and Pogz exist within the network. A high-resolution image is available: <http://fraenkel-nsf.csbi.mit.edu/psiquic/>.

transcription factors, and 43 nodes are differentially expressed mRNAs. This sub-network includes an additional 7 experimental genes from the RNAi input set; this yields a total of 40 transcription factors in the whole network, combining the two sub-networks. These 7 targets are transcription factors which had predicted connections to altered mRNAs, but did not have further connections to the protein–protein interaction network. This set of transcription factors comprises Tfdp1, Foxo6, Hmga2, Meis1, Myt1, Cebpa, and Klf3. Another identified transcription factor, Pparg, had connectivity both to the protein–protein interactome and directly to differential mRNA (Fig. 3 and 4).

Integrated approach finds genes connecting disparate data sets

This network further specifies interactions specific to either the *in vivo* or *in vitro* screen, as well as interactions common to both screens (Fig. 3 and 4). The network identified genes hits that connected the *in vitro* data (e.g. HGS, ARR, CASP10)

or the *in vivo* data (e.g. CPSF6, WWP1, TCF4, KLF5, HOXA9), and genes that connected data from both screens (e.g. IKBKB, NFKBIA, RELA).

We can also use the predicted genes identified by the algorithm to enhance the ability to identify known pathways using Gene Ontology (GO) functional enrichment statistics. Functional enrichment of the network genes compared to the whole genome identified GO processes distinct from those identified in the RNAi or mRNA expression data alone (Table 5). The processes include many associated with hematopoiesis including leukocyte homeostasis (q -value: 9.76×10^{-10}), lymphocyte homeostasis (q -value: 1.67×10^{-9}), regulation of leukocyte differentiation (q -value: 2.05×10^{-8}), hemopoiesis (q -value: 4.16×10^{-8}), and positive regulation of lymphocyte proliferation (q -value: 1.97×10^{-4}). These processes included B-cell specific functions such as negative regulation of cell differentiation (q -value: 4.92×10^{-10}) which reflect the undifferentiated




Table 6 Aggregate scoring of top network nodes. Genes are grouped by type (transcription factor, phenotypic, and hidden) and contextual effect. The shading in the right columns refers to colors from the network key in Fig. 3 and 4

Phenotypic Hits		
Node	Aggregate Score	
Rpl7	0.811	in vivo
Lap3	0.811	
Sf3a1	0.803	in vivo
Pogz	0.803	
Lat	0.836	in vivo
Tprkb	0.835	
Zbtb24	0.835	in vivo
Itgb1bp1	0.835	
Sclt1	0.835	in vivo
Ppp3cb	0.828	
Fcrl5	0.828	in vivo
Rcor2	0.828	

Hidden Nodes		
Node	Aggregate Score	
Usp7	0.436	Common
Tbp	0.430	
Traf2	0.301	Common
Ube2d1	0.277	
Ube2i	0.265	Common
Arnt	0.261	
Klf6	0.840	in vivo
Map3k14	0.840	
Tsg101	0.840	in vivo
Smurf2	0.840	
Trim24	0.840	in vivo
Plscr1	0.840	
Wwp1	0.838	in vivo
Skil	0.832	
Lmo2	0.824	in vivo
Tcf4	0.823	
2810408M09Rik	0.833	in vivo
Mid1	0.833	
Rabac1	0.816	in vivo
Aip	0.807	
Hgs	0.800	in vivo
Tbc1d4	0.800	

Transcription Factors		
Node	Aggregate Score	
Hmga2	0.897	Phenotypic
Klf3	0.887	
Tfdp1	0.883	in vivo
Foxo6	0.855	
Stat5a	0.496	common
Pelp1	0.457	
Gabpb1	0.832	in vivo
Foxo1	0.831	
Sp3	0.750	Hidden
Atf4	0.749	

homeostasis. The enrichment analysis also identified pathways with known relationships to leukemias, if not specifically acute lymphoblastic leukemia. We address the potential significance of these pathways in the discussion.

Predicted pathway contains genes contributing to ALL progression specifically *in vivo* and genes affecting B-cell viability

As initial evidence supporting the effective capabilities of our integrative pathways-based modeling approach, we note that the model predicts *in vivo* specific effects for Lmo2 and Pogz. These two targets have, in fact, been previously validated successfully.²⁰ For additional evidence, we undertook here new dedicated experimental tests of predicted hidden genes selected from the model-determined ranking list (Table 6). From the ranked gene list (Table 6), we used *in vivo* competition assays to measure the effects of loss of these predicted genes on ALL progression.

Hgs is a vesicular body-associated protein and was not included in our initial library screen. The model predicts that shRNAs targeting Hgs will deplete *in vitro*. In competition assays, an shRNA against Hgs depleted in culture, the blood, bone marrow, and spleen. The depletion in culture was greater than in all organs and was consistent with our model predictions (Fig. 5). These findings suggest that while Hgs confers a growth disadvantage to a pre-B-cell ALL, the *in vivo* environment mitigates the effect of Hgs loss. This may be due to growth factors or other paracrine signals that are relevant to hematological malignancies,¹⁹ direct cell-to-cell contact, disease compartmentalization, or many other factors unique to the *in vivo* environment.²⁰

Wwp1, is a ubiquitin conjugating enzyme that was in our initial library, however the sequencing reads were below the limit of detection, suggesting a bad shRNA reagent. The model predicts that Wwp1 knockdown has an *in vivo* specific effect, and competition assays confirm this phenotype. shWwp1 enriches in the blood, bone marrow, and spleen (Fig. 5).

Discussion

Discovering pathways *de novo* by leveraging multiple 'omics measurements can find latent information from functional genomic screens. We confirm the relevance of our model first through GO analysis. GO enrichment of the input RNAi and mRNA expression sets found no enrichment of relevant functions. This reaffirmed the disparate nature of individual data sets and suggested the possible value of an integrated approach. Further, we validated specific gene predictions from our network model. The model predicted an *in vivo* specific effect for Lmo2 and Pogz. They were functionally related to the very top gene targets as predicted by the pathway model, and were found to have *in vivo* specific effects through further validation. Hgs and Wwp1 were not included in the original screen analysis due to low sequencing coverage, yet the model predicted their relevance. Without such a model, they may never have been considered. Through focused validation, they both proved relevant to ALL progression.







Fig. 5 Validation shows *in vitro* and *in vivo* effects for Hgs and Wwp1. In the competition assays, we measure the relative abundances of pre-B-cells with and without an shRNA against our gene of interest either in culture or transplanted into mice. We measure relative proportions at the time of morbidity using FACS. All plots are mean \pm S.D. For all samples, $n = 3$, except for Hgs, and Wwp1 tissue samples where $n = 4$.

The model makes many predictions about genes with roles in development that have unclear roles in ALL. Many of these development-associated genes are implicated across leukemias, though degree of expression and directionality of their effects can be context dependent. Some transcription factors, such as TCF3, PAX5, IKZF1, and EBF1, are involved during many hematopoietic stages.²⁸ Other network genes are characteristic of non-ALL leukemias. For instance, our network selects the transcription factor TCF4. This factor is up-regulated in the solid tumors of adult T-cell ALL patients²⁹ but currently has an unknown roll in B-cell ALL, though it is highly expressed in this pre-B-cell ALL system. Additionally, functional enrichment identifies that network genes are enriched for the TGF-beta growth factor pathway process. Multiple leukemias, including chronic myelogenous (CML), acute T-cell leukemia (ATL), and ALL, express TGF-beta associated genes. Though, expression of TGF-beta components was higher in the T-cell leukemias than in the other leukemic cell lines³⁰ and the ATL samples responded to exogenous TGF-beta. Further, TGF-beta and Foxo3a activity both promote the maintenance of leukemia-initiating cells in CML³¹ and loss of Foxo3a and TGF-beta inhibition better sensitized cells to Imatinib treatment. Clinically, patients with higher levels of TGF-beta are considered high-risk, as they often harbor additional mutations that prevent the tumor-suppressor roles of TGF-beta.³² The network also identifies the Wnt signaling pathway which is relevant in multiple hematological malignancies; specifically, stabilized beta-catenin is associated with differentiation arrest, is highly expressed in childhood T-cell ALL, and Wnt signaling can promote drug resistance.^{29,33–35} Hemopoiesis is governed by stage- and lineage-specific transcription factor regulation^{28,29} and finding relationships between differentiation and disease genes is valuable for understanding ALL generally. These predictions underscore our incomplete knowledge of this disease pathway. Additionally, specific network predictions are useful for translating therapeutic insight into ALL; specifically investigating

TGF-beta and Wnt in ALL will inform research in therapeutics as these pathways have already been characterized in other leukemic contexts.

The network predictions about genes associated with B-cell development are relevant for interpreting therapeutic resistance. B-cell development pathways have been identified as hallmarks of drug-resistant leukemias and thus, therapeutic strategies promoting B-cell maturation show promise.¹⁷ Previous studies have also demonstrated the role of histone modification pathways in relapsed ALL; specifically CREBBP and CTCF, are mutated in these patients and may affect treatment response.³⁶ The network confirms the relevance of CREBBP to pre-B-cell ALL, though, the model indicates that this gene is deleterious to B-cell viability and does not specifically modulate the response not specific to the *in vivo* environment. Identifying developmental pathways in ALL is not novel, but there is novelty in specifying which of these genes are deleterious for pre-B-cell growth and those that are deleterious *in vivo*.

We develop our model to select for context-specific interactions and can identify genes relevant to the *in vitro* or *in vivo* settings, or genes that are common to both. In the case of Hgs, the model predicts an *in vitro* specific effect. We demonstrate that Hgs loss confers a growth disadvantage in culture, blood, spleen, and bone marrow, but that this loss is most drastic in culture. This trend emphasizes the ability to distinguish genes relevant to the pre-B-cell model and those specifically responding to the cancer microenvironment. In the case of Hgs, loss of this gene is significant in culture, blood, spleen, and bone marrow, though our model predicts and confirms that this is not an effect specific to the tumor microenvironment. This framework is valuable as screening context (*e.g.* treatments or experimental environment) can affect which parts of a pathway are relevant. In our example, all genes in the model are predicted as part of the ALL pathway, but only a subset are relevant to ALL progression *in vivo*.



Hgs (Hrs) is a member of the ESCRT-0 family of proteins involved with multivesicular body (MVB) formation.³⁷ This protein is involved with the internalization and degradation of activated cell-surface receptors^{38,39} and loss of Hrs is associated with increased accumulation of E-cadherin and decreased cell proliferation.³⁸ Hrs is also essential for the termination of IL-6 signals by sorting gp130, a transducer of IL-6 stimulation, for endosomal degradation.⁴⁰ Further, Hrs deficiency in mice decreased B-cell receptor expression; BCR expression is necessary for pre-B-cell expansion.^{39,41} The consequences of Hgs loss suggest that deficiencies in receptor internalization are deleterious to this type of pre-B-cell ALL.

The network predicts a novel role for Wwp1 in pre-B-cell ALL. Even though the network model was constructed using shRNAs that conferred a growth disadvantage, the model does not predict the directionality of effects for predicted genes. Validation experiments confirmed that Wwp1 had an *in vivo* specific effect, and that Wwp1 loss conferred a growth advantage. This enrichment is surprising because so far, most evidence suggests that Wwp1 is an oncogene; our competition assays suggests that in ALL, Wwp1 may have a tumor suppressor role. WWP1 is a member of the Nedd4 family of ubiquitin ligases, many of which are over-expressed in cancer.⁴² Many results suggest that WWP1 acts an oncogene by targeting tumor-suppressing proteins, such as LATS, for degradation. WWP1 is over-expressed in breast and prostate cancers, and seems to function in this oncogenic manner.^{43,44} Though, WWP1 also participates in a unique feedback loop with p53. Wwp1 stabilizes p53 protein in the cytoplasm, but decreases its expression, and in turn, p53 reduces the expression of Wwp1.⁴⁵ This feedback loop is dependent upon p53 mutation status; mutated p53 abrogates this feedback dynamic leading to increased Wwp1 expression. In our pre-B-cell ALL, Wwp1 has relatively low expression and intact p53 suggesting an intact feedback loop. Loss of Wwp1 could lead to decreased p53 protein stability and enable interactions with other proteins. For instance, these cells express high levels of survivin (Birc5), which can prevent p53-mediated apoptosis in pediatric ALL.⁴⁶

Off target effects are one of the largest criticisms of RNAi screens, yet even with these effects, we construct and validate a model for genes regulating ALL progression. We create this model with less than 100 input targets from each screen and find GO enrichment of genes related to leukemia and hematopoietic development. This demonstrates that the network filter is sufficiently powerful for analysis of screening data and that even stringent thresholds are sufficient for identifying genes relevant to a pathway. Further, we perform this analysis retroactively without controlling for OTEs or requiring specific negative controls, showing that RNAi analyses do not have to specifically compensate for OTEs. This suggests that even with limited and imperfect screening results, we can learn more from these screens, and that pathway discovery approaches are a viable path forward for the gene-interference community.

There are limitations associated with this approach. We have not yet made an estimate of validation rate for these network-based filters. To make this estimate, we would need to validate

all genes in the network and determine the false positive rate. This method requires multiple datasets to create a possible network whereas other approaches require fewer input datasets. Some examples of tools that require a single input dataset include the Prize Collecting Steiner Forest (PCSF),^{47,48} TieDIE,⁴⁹ and HOTNET.^{50,51} For a biologist, these tools could be easier to implement, but they lack the perspective gained by integrating multiple 'omic measurements. Each 'omic measurement captures a slightly different aspect of the cellular process under investigation, and so there are trade-offs between completeness and simplicity when selecting these tools.

Application of integration methods will improve understanding of gene-interference screens regardless of improvements in reagent design. CRISPR systems are more sensitive than RNAi and are better suited for discovering essential human genes.^{52,53} Though, both technologies are limited by biological compensation through alternative pathways or redundant proteins. Thus, adapting and applying interaction-based methods for data integration will continue to be of importance for functional genomic investigations. These integration methods can impact many biological problems beyond cancer investigations. To cite a few examples, RNAi screens are useful for uncovering synthetic lethal relationships,⁵⁴ genes associated with homologous recombination,⁵⁵ and genes responsible for ectodomain shedding.⁵⁶ Many have promoted the value of data integration analysis methods,^{2,4,8,21} however, these analysis approaches remain under utilized in the gene interference community.

Materials and methods

shRNA screen, and data processing

The original shRNA screen and mRNA expression data are described previously.²⁰ DESEQ2 size-factor normalized and calculated fold-changes for shRNA sequencing data. We ranked these fold-change values by *p*-value from DESEQ2.⁵⁷ The GOrilla tool (<http://cbl-gorilla.cs.technion.ac.il/>)^{21,22} determined GO functional enrichment using the top 1% of differentially depleted shRNAs against the background of the whole mouse genome. GOrilla also determined functional enrichment of the top 1% of differentially expressed (up-regulated/down-regulated mRNAs for the *in vivo/in vitro* contexts) mRNAs against the background of the whole mouse genome.

Cell culture and ChIP-seq

Pre-B-cell ALL cells^{58,59} were cultured as published.²⁰ We performed ChIP assays as previously described.⁶⁰ Briefly, 8.5×10^6 pre-B-cells were cross-linked with 11% formaldehyde. Pellets were lysed and sonicated using the BioRuptor. Following sonication, activated DNA regions were immunoprecipitated using the following antibodies: K4me3 (Millipore Lot#1974075), K27Ac (Abcam Lot#GR1048521), and IgG (Millipore Lot#JBC17938060).

Peak and valley finding

We used the MACS algorithm⁶¹ to identify peak regions 10k kb upstream of the transcription start site. Within these peak regions, we searched for valleys (local minima within peak



regions) and then used these regions as inputs for potential transcription factor binding locations. The ChIP-seq data are available: GSE77570 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77570>). To discover valleys, we create a script that looks for local minima surrounding peaks in the H3K4me3 and H3K27Ac datasets. We use MACS⁶¹ to define significant peaks in each ChIP-seq data set and then define local minima between peaks. Our definition requires that a “minimum” region be less than half the height of the shorter of two neighboring peaks. This approach is motivated by the fact that transcriptional enhancers are more likely to bind in between histones and we needed these sequences to identify transcription factor motif regions. Previous work demonstrated that transcription factor binding is correlated with local minima in ChIP-seq data,⁶² and additional work has used these “dips” to look for enriched transcription factor motifs.⁶³

Interactome construction

We used Garnet to create transcription factor to DNA binding interactions. The Garnet package uses a weighted scoring function²² to determine which transcription factor motifs were the most likely to bind a set of Fasta sequences. For input, we used the valleys identified from our previously mentioned ChIP-seq data. The software is part of a suite of ‘omics integration tools (<http://fraenkel.mit.edu/omicsintegrator>).

For our starting interaction network, we downloaded interactions from iRefWeb version 9 and we only kept interactions that mapped to UNIPROT reviewed human proteins. These interactions were scored using the miscore framework⁶⁴ to create a probabilistically-weighted interactome. This score considers the number of publications, the type of interaction, and the evidence supporting the interaction. We discarded interactions with a score below 0.3. This yielded a starting network of 88 117 interactions. The interactome is hosted on the Fraenkel Lab Website (<http://fraenkel-nsf.csbi.mit.edu/psiquic/>).

Simultaneous analysis of multiple networks (SAMNet)

We built the model using SAMNet.²⁶ We used the top 1% of depleted shRNAs (for *in vivo* and *in vitro*), the top 1% differentially expressed mRNAs (up-regulated genes were assigned prizes for the *in vivo* context and down-regulated genes were assigned prizes for the *in vitro* context), the transcription factor to DNA binding interactions, and the weighted interactome as inputs to the algorithm. For simplicity, we mapped all mouse data to human gene symbols using homology. We used a gamma parameter of 17 as this was found to maximize the number of shRNA-targeted genes in the network. We again used GOrilla to determine the functional enrichment of the network, this time using the set of network nodes as a foreground against the background of the whole mouse genome.

Randomizations and robustness analysis

For randomizations, we completed 100 runs of the algorithm at the same gamma parameter, but with the depletion and differential expression scores distributed to random sets of genes. We calculated node enrichment fraction, or specificity,

by counting the number of times a node from the real network was selected in a random network. For further scoring and ranking, we used 1-specificity to keep all network parameters on a 0–1 scale. We used networkx in Python to determine the authority scores for network genes. SAMNet outputs the amount of flow converging on a gene. Our aggregate scoring method weighted each of these normalized values by the standard deviation of these metrics across all genes and was normalized to the sum of all metric standard deviations:

$$R = \frac{(1\text{-specificity}) \times \sigma_{(1\text{-specificity})} + \text{authority} \times \sigma_{\text{authority}} + \text{flow} \times \sigma_{\text{flow}}}{\sigma_{(1\text{-specificity})} + \sigma_{\text{authority}} + \sigma_{\text{flow}}}$$

We completed this calculation separately for genes unique to *in vivo/in vitro* contexts and common between both contexts because common genes had two authority and flow scores. Because we designed the model to allow for multiple out-going connections from transcription factors but not from hidden genes and because phenotypic (shRNA) hits did not have incoming flow in the mode, we created separate rankings for transcription factors and phenotypic hits.


GFP competition assays

For model validation, we conducted parallel *in vitro* and *in vivo* GFP competition assays. We created shRNA constructs for Hgs and Wwp1, and infected pure populations of mCherry positive ALL cells as described.²⁰ At the time of experiment, infected pre-B-cells were mixed 50 : 50 with mCherry positive ALL cells. From these populations, 100k cells were tail-vein injected into four 8-week-old, female C57BL6 mice, and 100k cells were plated in triplicate. Cultured populations were split 1 : 5 daily until mice reached morbidity (10–12 days following injection). At the time of morbidity, we collected blood, spleen, and bone marrow. For all *in vivo* and *in vitro* samples, we measure the %GFP of mCherry-labeled cells and calculated a fold-change relative to the 50 : 50 ratio at input. We normalized %GFP-fold-change to the MLS control for the respective tissue and used a *t*-test with Welch’s correction to determine significance. The sequences used for Hgs and Wwp1 shRNAs are CCAGAAAC CACTTATATGTCTA and CTCCTATTTTATACAGAGCAA. We tested shRNA knockdown using qPCR relative to Gapdh using Taqman expression assays. shHgs and shWwp1 left 23.28% and 67.64% mRNA remaining (Fig. S1, ESI†).

All experiments were performed in compliance with the relevant laws and institutional guidelines. Animal protocols were submitted to and approved by the MIT CRC. Animals were housed in compliance with the DCM policies for live subjects.

Author contributions

Douglas A. Lauffenburger (D. A. L.), Ernest Fraenkel (E. F.), Michael Hemann (M. H.), Sara Gosline (S. G.), Simona Dalin (S. D.), and Jennifer L. Wilson (J. L. W.). D. A. L., E. F., J. L. W., and S. G. designed the project; J. L. W. and S. D. performed research; E. F., D. A. L., M. H., and S. G., contributed new



reagents/analytic tools; J. L. W. analyzed data; J. L. W. wrote the paper; and E. F., and D. A. L. supervised all aspects of the work.

Availability of data and materials

The interactome dataset used for modeling is available on the Fraenkel Lab website, <http://fraenkel-nsf.csbi.mit.edu/psiquic/>.

The CHIP-seq data are available in the GEO repository under identifier GSE77570, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77570>.

An online version of our algorithm, SAMNetWeb,⁶⁵ is available online (<http://fraenkel-nsf.csbi.mit.edu/samnetweb/>), and the full version is available on GitHub: <https://github.com/sgosline/SAMNet>. An archived version of the code used to create this manuscript is available on the Fraenkel Lab website, <http://fraenkel-nsf.csbi.mit.edu/psiquic/>.

List of abbreviations

ALL	Acute lymphoblastic leukemia
GO	Gene ontology
OTE	Off-target effects
RNAi	RNA interference
SAMNet	Simultaneous analysis of multiple networks (algorithm)

Funding

The work was supported by the NIH grants NIH Grant U01-CA155758, U54-CA112967 (D. A. L.), U01-CA184898 (E. F.), U01-CA155758 (M. H.), and NSF GRFP and Koch Graduate Fellowship (J. L. W.). Computing resources were partially supported by the National Science Foundation Grant DB1-0821391 and sequencing was partially supported by the National Institutes of Health Grant P30-ES002109.

Acknowledgements

We acknowledge support from the Koch Flow Cytometry Core and express appreciation to Eleanor Fiedler, and the Biological Engineering Communication Lab for helpful discussion and support, Jordan Bartlebaugh, and Azucena (Susy) Ramos for experimental advice and guidance.

References

- 1 S. Mohr, C. Bakal and N. Perrimon, *Annu. Rev. Biochem.*, 2010, **79**, 37–64.
- 2 J. L. Wilson, M. T. Hemann, E. Fraenkel and D. A. Lauffenburger, *Sem. Cancer Biol.*, 2013, **23**, 213–218.
- 3 M. Fennell, Q. Xiang, A. Hwang, C. Chen, C. H. Huang, C. C. Chen, R. Pelossof and R. J. Garippa, *J. Biomol. Screening*, 2014, **19**, 1327–1337.
- 4 S. E. Mohr, J. A. Smith, C. E. Shamu, R. A. Neumüller and N. Perrimon, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 591–600.
- 5 M. Boettcher and M. T. McManus, *Mol. Cell*, 2015, 575–585.
- 6 J. Taylor and S. Woodcock, *J. Biomol. Screening*, 2015, **20**, 1040–1051.
- 7 A. L. Jackson and P. S. Linsley, *Nat. Rev. Drug Discovery*, 2010, 1–11.
- 8 F. D. Sigoillot, S. Lyman, J. F. Huckins, B. Adamson, E. Chung, B. Quattrochi and R. W. King, *Nature*, 2012, **9**, 363–366.
- 9 W. G. Kaelin, *Science*, 2012, **337**, 421–422.
- 10 A. L. Jackson, *RNA*, 2006, **12**, 1197–1205.
- 11 A. Rapkiewicz, V. Espina, J. A. Zujewski, P. F. Lebowitz, A. Filie, J. Wulfkühle, K. Camphausen, E. Petricoin, L. Liotta and A. Abati, *Cancer*, 2007, **111**, 1–12.
- 12 E. Buehler, A. A. Khan, S. Marine, M. Rajaram and A. Bahl, *Sci. Rep.*, 2012, 1–6.
- 13 L. A. Gilbert, M. A. Horlbeck, B. Adamson, J. E. Villalta, Y. Chen, E. H. Whitehead, C. Guimaraes, B. Panning, H. L. Ploegh, M. C. Bassik, L. S. Qi, M. Kampmann and J. S. Weissman, *Cell*, 2014, **159**, 647–661.
- 14 T. J. Cradick, E. J. Fine, C. J. Antico and G. Bao, *Nucleic Acids Res.*, 2013, 1–9.
- 15 F. D. Bushman, N. Malani, J. Fernandes, I. D'Orso, G. Cagney, T. L. Diamond, H. Zhou, D. J. Hazuda, A. S. Espeseth, R. König, S. Bandyopadhyay, T. Ideker, S. P. Goff, N. J. Krogan, A. D. Frankel, J. A. T. Young and S. K. Chanda, *PLoS Pathog.*, 2009, **5**, e1000437.
- 16 J. M. Rowe, *Best Pract. Res., Clin. Haematol.*, 2015, **28**, 69–72.
- 17 J. A. E. Irving, *Br. J. Haematol.*, 2015, 656–666.
- 18 T. Hideshima, C. Mitsiades, G. Tonon, P. G. Richardson and K. C. Anderson, *Nat. Rev. Cancer*, 2007, **7**, 585–598.
- 19 L. A. Gilbert and M. T. Hemann, *Genes Dev.*, 2012, **26**, 1758–1768.
- 20 C. E. Meacham, L. N. Lawton, Y. M. Soto-Feliciano, J. R. Pritchard, B. A. Joughin, T. Ehrenberger, N. Fenouille, J. Zuber, R. T. Williams, R. A. Young and M. T. Hemann, *Genes Dev.*, 2015, **29**, 483–488.
- 21 E. Eden, D. Lipson, S. Yogev and Z. Yakhini, *PLoS Comput. Biol.*, 2007, **3**, e39.
- 22 E. Eden, R. Navon, I. Steinfeld, D. Lipson and Z. Yakhini, *BMC Bioinf.*, 2009, **10**, 48.
- 23 E. Yeger-Lotem, L. Riva, L. J. Su, A. D. Gitler, A. G. Cashikar, O. D. King, P. K. Auluck, M. L. Geddie, J. S. Valastyan, D. R. Karger, S. Lindquist and E. Fraenkel, *Nat. Genet.*, 2009, **41**, 316–323.
- 24 C. W. Ng, F. Yildirim, Y. S. Yap, S. Dalin, B. J. Matthews, P. J. Velez, A. Labadorf, D. E. Housman and E. Fraenkel, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, 1–6.
- 25 N. Tuncbag, S. J. C. Gosline, A. Kedaigle, A. R. Soltis, A. Gitter and E. Fraenkel, *PLoS Comput. Biol.*, 2016, e1004879.
- 26 S. Gosline, S. Spencer and E. Fraenkel, *Integr. Biol.*, 2012, 1415–1427.
- 27 C. Cobaleda and I. S. García, *BioEssays*, 2009, 600–609.
- 28 R. Somasundaram, M. Prasad and J. Ungerback, *Blood*, 2015, 144–152.
- 29 O. H. Ng, Y. Erbilgin, S. Firtina, T. Celkan and Z. Karakas, *Blood Cancer J.*, 2014, 1–8.



- 30 Y. Niitsu, Y. Urushizaki, Y. Koshida, K. Terui and K. Mahara, *Blood*, 2015, 1–5.
- 31 K. Naka, T. Hoshii, T. Muraguchi, Y. Tadokoro, T. Ooshio, Y. Kondo, S. Nakao, N. Motoyama and A. Hirao, *Nature*, 2010, **463**, 676–680.
- 32 J. R. Downing, *N. Engl. J. Med.*, 2004, **351**, 528–530.
- 33 T. K. Fung, A. Leung and C. So, *Stem Cells and Cancer Stem Cells*, 2013.
- 34 W. Fiskus, S. Sharma, S. Saha, B. Shah, S. G. T. Devaraj, B. Sun, S. Horrigan, C. Leveque, Y. Zu, S. Iyer and K. N. Bhalla, *Leukemia*, 2014, **29**, 1267–1278.
- 35 E. Ashihara, T. Takada and T. Maekawa, *Cancer Sci.*, 2015, **106**, 665–671.
- 36 C. G. Mullighan, J. Zhang, L. H. Kasper, S. Lerach, D. Payne-Turner, L. A. Phillips, S. L. Heatley, L. Holmfeldt, J. R. Collins-Underwood, J. Ma, K. H. Buetow, C.-H. Pui, S. D. Baker, P. K. Brindle and J. R. Downing, *Nature*, 2011, **471**, 235–239.
- 37 J. R. Edgar, E. R. Eden and C. E. Futter, *Traffic*, 2014, 197–211.
- 38 M. Toyoshima, N. Tanaka, J. Aoki, Y. Tanaka, K. Murata, M. Kyuuma, H. Kobayashi, N. Ishii, N. Yaegashi and K. Sugamura, *Cancer Res.*, 2007, **67**, 5162–5171.
- 39 T. Nagata, K. Murata, R. Murata, S.-L. Sun, Y. Saito, S. Yamaga, N. Tanaka, K. Tamai, K. Moriya, N. Kasai, K. Sugamura and N. Ishii, *Biochem. Biophys. Res. Commun.*, 2014, **443**, 351–356.
- 40 Y. Tanaka, N. Tanaka, Y. Saeki, K. Tanaka, M. Murakami, T. Hirano, N. Ishii and K. Sugamura, *Mol. Cell. Biol.*, 2008, **28**, 4805–4818.
- 41 M. Zhang, G. Srivastava and L. Lu, *Cell. Mol. Immunol.*, 2004, **1**, 89–94.
- 42 C. Chen and L. E. Matesic, *Cancer Metastasis Rev.*, 2007, **26**, 587–604.
- 43 Z. Zhongmei, R. Liu and C. Chen, *Int. J. Cancer*, 2011, **130**, 1504–1510.
- 44 B. Yeung, K.-C. Ho and X. Yang, *PLoS One*, 2013, **8**, e61027.
- 45 A. Laine and Z. Ronai, *Oncogene*, 2006, **26**, 1477–1483.
- 46 J. W. Tyner, A. M. Jemal, M. Thayer, B. J. Druker and B. H. Chang, *Leukemia*, 2012, 623–632.
- 47 S.-S. C. Huang and E. Fraenkel, *Sci. Signaling*, 2009, **2**, ra40.
- 48 N. Tuncbag, A. Braunstein, A. Pagnani, S.-S. C. Huang, J. Chayes, C. Borgs, R. Zecchina and E. Fraenkel, *J. Comput. Biol.*, 2013, **20**, 124–136.
- 49 E. O. Paull, D. E. Carlin, M. Niepel, P. K. Sorger, D. Haussler and J. M. Stuart, *Bioinformatics*, 2013, **29**, 2757–2764.
- 50 F. Vandin, E. Upfal and B. J. Raphael, *Lecture Notes in Computer Science*, Springer Berlin Heidelberg, Berlin, Heidelberg, 2010, vol. 6044, pp. 506–521.
- 51 F. Vandin, E. Upfal and B. J. Raphael, *J. Comput. Biol.*, 2011, **18**, 507–522.
- 52 T. Hart, K. R. Brown, F. Sircoulomb, R. Rottapel and J. Moffat, *Mol. Syst. Biol.*, 2014, **10**, 733.
- 53 T. Hart, M. Chandrashekar, M. Aregger, Z. Steinhart, K. R. Brown, S. Angers and J. Moffat, *Systematic discovery and classification of human cell line essential genes*, 2015.
- 54 C. Scholl, S. Fröhling, I. F. Dunn, A. C. Schinzel, D. A. Barbie, S. Y. Kim, S. J. Silver, P. Tamayo, R. C. Wadlow, S. Ramaswamy, K. Döhner, L. Bullinger, P. Sandy, J. S. Boehm, D. E. Root, T. Jacks, W. C. Hahn and D. G. Gilliland, *Cell*, 2009, **137**, 821–834.
- 55 B. Adamson, A. Smogorzewska, F. D. Sigoillot, R. W. King and S. J. Elledge, *Nat. Cell Biol.*, 2012, **14**, 318–328.
- 56 M. Dang, K. Dubbin, A. D'Aiello, M. Hartmann, H. Lodish and A. Herrlich, *J. Biol. Chem.*, 2011, **286**, 17704–17713.
- 57 S. Anders and W. Huber, *Genome Biol.*, 2010, **11**, R106.
- 58 R. T. Williams, M. F. Roussel and C. J. Sherr, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 6688–6693.
- 59 R. T. Williams, W. den Besten and C. J. Sherr, *Genes Dev.*, 2007, **21**, 2283–2287.
- 60 K. D. MacIsaac and E. Fraenkel, *Computational Biology of Transcription Factor*, 2010.
- 61 J. Feng, T. Liu and Y. Zhang, *Current Protocols in Bioinformatics*, 2011.
- 62 S. A. Ramsey, T. A. Knijnenburg, K. A. Kennedy, D. E. Zak, M. Gilchrist, E. S. Gold, C. D. Johnson, A. E. Lampano, V. Litvak, G. Navarro, T. Stolyar, A. Aderem and I. Shmulevich, *Bioinformatics*, 2010, **26**, 2071–2075.
- 63 J. A. Wamstad, J. M. Alexander, R. M. Truty and A. Shrikumar, *Cell*, 2012, 206–220.
- 64 J. M. Villaveces, R. C. Jimenez, P. Porras, N. del-Toro, M. Duesbury, M. Dumousseau, S. Orchard, H. Choi, P. Ping, N. C. Zong, M. Askenazi, B. H. Habermann and H. Hermjakob, *Database*, 2015, **2015**, bau131.
- 65 S. Gosline, C. Oh and E. Fraenkel, *Bioinformatics*, 2015, 1124–1126.

